Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer.

Sci Rep · 2025 · PMC12181351 · PMID 40542015

Europe PMC DOI

hedged sentence

0.0032

closest p · 0.1× alpha

0.0032

boldest claim

The sentences

highly significantp = 0.0032actually significant

This is a highly significant difference compared to group 1 (65.8%; p = 0.0032) and group 2 (64.5%; p = 0.0029) (data not shown).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.